Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis (2020) Zhang Y, Zhu H, Layritz F, Luo H, Wohlfahrt T, Chen CW, Soare A, et al. Journal article Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis (2020) Soare A, Györfi AH, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, et al. Journal article Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits (2019) Ellmann H, Bayat S, Guilhon de Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, et al. Journal article Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis (2019) Kozlova A, Pachera E, Maurer B, Juengel A, Distler J, Kania G, Distler O Journal article Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients (2019) Schett G, Simon D, Hueber A, Bang H, Rech J, Krönke G, Kleyer A Conference contribution Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort (2019) Tascilar K, Aydin SZ, Akar S, Aksu K, Bakirci S, Bayindir O, Can M, et al. Conference contribution Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial (2019) Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution